



Gossamer Bio Announces Participation in Upcoming Investor Conferences

June 1, 2020

SAN DIEGO--(BUSINESS WIRE)--Jun. 1, 2020-- [Gossamer Bio, Inc.](#) (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its participation in two upcoming investor conferences. Chief Executive Officer and Co-Founder Sheila Gujrathi, M.D., will present at the Jefferies Virtual Healthcare Conference on Thursday, June 4, at 3:00 p.m. ET and at the 41st Annual Goldman Sachs Global Healthcare Conference on Thursday, June 11, at 2:10 p.m. ET.

Live webcasts of both presentations will be available on the “Events and Presentations” page in the “Investors” section of the company’s website at <https://ir.gossamerbio.com>. Replays of each webcast will be archived on the company’s website for 90 days following the presentation.

About Gossamer Bio

Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20200601005175/en/): <https://www.businesswire.com/news/home/20200601005175/en/>

For Investors and Media:

Bryan Giraudo, Chief Financial Officer
Gossamer Bio Investor Relations
ir@gossamerbio.com

Source: Gossamer Bio, Inc.